Back to News & Events

Ohr Pharmaceutical & Cold Spring Harbor Laboratory Announce Joint Venture

Ohr Pharmaceutical, a pharmaceutical company focused on the development of novel therapeutics for large unmet medical needs, and Cold Spring Harbor Laboratory (CSHL) have announced the establishment of DepYmed Inc., a new joint venture to develop trodusquemine and related analogs.

The new joint venture will be a private entity, initially with equal ownership by Ohr and Cold Spring Harbor Laboratory. The two partners will seek funding and contribute to the research and development of trodusquemine and also newly patented analogs. The goal is to take the program into the clinic and to demonstrate proof of concept.

Andreas Grill, former Executive Director of Forest Research Institute for Forest Laboratories, Inc and current Center for Biotechnology BioEntrepreneur-inResidence has been tapped to serve as Chief Executive Office for DepYmed.

Read the full press release here.

Related Stories

WP_Query Object
(
    [query] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
        )

    [query_vars] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
            [error] => 
            [m] => 
            [p] => 0
            [post_parent] => 
            [subpost] => 
            [subpost_id] => 
            [attachment] => 
            [attachment_id] => 0
            [name] => 
            [pagename] => 
            [page_id] => 0
            [second] => 
            [minute] => 
            [hour] => 
            [day] => 0
            [monthnum] => 0
            [year] => 0
            [w] => 0
            [category_name] => 
            [tag] => 
            [cat] => 
            [tag_id] => 
            [author] => 
            [author_name] => 
            [feed] => 
            [tb] => 
            [paged] => 0
            [meta_key] => 
            [meta_value] => 
            [preview] => 
            [s] => 
            [sentence] => 
            [title] => 
            [fields] => 
            [menu_order] => 
            [embed] => 
            [category__in] => Array
                (
                )

            [category__not_in] => Array
                (
                )

            [category__and] => Array
                (
                )

            [post__in] => Array
                (
                )

            [post__not_in] => Array
                (
                )

            [post_name__in] => Array
                (
                )

            [tag__in] => Array
                (
                )

            [tag__not_in] => Array
                (
                )

            [tag__and] => Array
                (
                )

            [tag_slug__in] => Array
                (
                )

            [tag_slug__and] => Array
                (
                )

            [post_parent__in] => Array
                (
                )

            [post_parent__not_in] => Array
                (
                )

            [author__in] => Array
                (
                )

            [author__not_in] => Array
                (
                )

            [search_columns] => Array
                (
                )

            [ignore_sticky_posts] => 
            [suppress_filters] => 
            [cache_results] => 1
            [update_post_term_cache] => 1
            [update_menu_item_cache] => 
            [lazy_load_term_meta] => 1
            [update_post_meta_cache] => 1
            [nopaging] => 
            [comments_per_page] => 50
            [no_found_rows] => 
            [order] => 
        )

    [tax_query] => WP_Tax_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => AND
            [table_aliases:protected] => Array
                (
                )

            [queried_terms] => Array
                (
                )

            [primary_table] => wp_posts
            [primary_id_column] => ID
        )

    [meta_query] => WP_Meta_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => 
            [meta_table] => 
            [meta_id_column] => 
            [primary_table] => 
            [primary_id_column] => 
            [table_aliases:protected] => Array
                (
                )

            [clauses:protected] => Array
                (
                )

            [has_or_relation:protected] => 
        )

    [date_query] => 
    [request] => SELECT SQL_CALC_FOUND_ROWS  wp_posts.ID
					 FROM wp_posts 
					 WHERE 1=1  AND wp_posts.post_type = 'post' AND ((wp_posts.post_status = 'publish'))
					 
					 ORDER BY RAND()
					 LIMIT 0, 3
    [posts] => Array
        (
            [0] => WP_Post Object
                (
                    [ID] => 4439
                    [post_author] => 3
                    [post_date] => 2024-07-30 15:29:07
                    [post_date_gmt] => 2024-07-30 19:29:07
                    [post_content] => 

CFB Client, IAMBIC has been awarded approximately $1M in grant funding from the National Science Foundation Small Business Innovation Research program. IAMBIC is an innovative shoe company disrupting the centuries-old footwear industry with their sizeless, precision-fit footwear driven by proprietary AI algorithms. This substantial funding from NSF enables IAMBIC to scale its cutting-edge precision-fit shoe design and manufacturing.

The Center for Biotechnology and its accelerator programs have been instrumental in assisting IAMBIC with their SBIR pursuits and commercialization development.

Read more about IAMBIC and their recent funding here.

[post_title] => IAMBIC Receives $1 Million NSF SBIR Phase II Grant [post_excerpt] => This substantial funding from NSF enables IAMBIC to scale its operations. [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => iambic-receives-1-million-nsf-sbir-phase-ii-grant [to_ping] => [pinged] => [post_modified] => 2024-08-09 15:38:43 [post_modified_gmt] => 2024-08-09 19:38:43 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4439 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [1] => WP_Post Object ( [ID] => 2700 [post_author] => 4 [post_date] => 2017-05-19 18:26:24 [post_date_gmt] => 2017-05-19 18:26:24 [post_content] => Center for Biotechnology BioEntrepreneur-in-Residence and Founder and CEO of Traverse Biosciences, Joseph Scaduto, recently penned a powerful article discussing the importance of human capital to the growth and sustainability of New York’s bioscience ecosystem. "...the prospect of “jumping ship” into a new bioscience venture is not just risky, it is downright scary, if not financially impossible, exacerbated further by the frightening lack of alternative job opportunities in the high-probability event of failure. In my opinion, this seemingly insurmountable and geographic “barrier to entry,” defined by the comparatively excessive risk of bioentrepreneurship, is a primary reason why New York continues to struggle to develop, cultivate and grow a vibrant, dynamic and self-sustaining bioscience industry cluster." Read the full article here.   [post_title] => Getting Serious About BioEntrepreneurship in New York [post_excerpt] => "The prospect of “jumping ship” into a new bioscience venture is not just risky, it is downright scary, if not financially impossible, exacerbated further by the frightening lack of alternative job opportunities in the high-probability event of failure." [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => getting-serious-about-bioentrepreneurship-in-new-york [to_ping] => [pinged] => [post_modified] => 2017-08-08 15:53:19 [post_modified_gmt] => 2017-08-08 15:53:19 [post_content_filtered] => [post_parent] => 0 [guid] => http://centerforbiotechnology.org/?p=2700 [menu_order] => 145 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [2] => WP_Post Object ( [ID] => 4285 [post_author] => 4 [post_date] => 2023-09-11 12:13:16 [post_date_gmt] => 2023-09-11 16:13:16 [post_content] =>

Join Stony Brook University’s Intellectual Property Partners on Thursday, October 12, from 4:30 pm to 6 pm at the Charles B. Wang Center at Stony Brook University for the panel discussion titled “Bring Your New Technology Innovations to Life Through Prototyping and Manufacturing.”

The event will be hosted by Intellectual Property Partners (IPP), the SBU Chapter of the National Academy of Inventors (NAI), and the Manufacturing and Technology Resource Consortium (MTRC) and will be followed by a networking cocktail reception from 6 pm to 7 pm.

Moderated by Dr. James Hayward, President, CEO and Chairman of Applied DNA Sciences, panelists include:
– Adrian Howansky, PhD, Clinical Medical Physicist, Department of Radiology, Stony Brook University Hospital
– Doreen Swift, Senior Director, Embedded Software Engineering, IPS
– Michael R. Bielski, President, DevTech Partners
– Nariman Boyle, MD, Director, Ophthalmic Plastic Orbit and Reconstructive Surgery, Department of Ophthalmology, Renaissance School of Medicine, Stony Brook University
– Paul Schwartz, Director, Advanced Propulsion Technologies

This event is free and open to Stony Brook University attendees. Space is limited and registration is required. Register here to secure your spot.

For more information visit: https://www.stonybrook.edu/commcms/ipp/Events/Manufacturing.php

[post_title] => "Bring Your New Technology Innovations to Life Through Prototyping and Manufacturing" 10/12/23 [post_excerpt] => Join Stony Brook University’s Intellectual Property Partners on October 12th for the panel discussion titled “Bring Your New Technology Innovations to Life Through Prototyping and Manufacturing.” [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => bring-your-new-technology-innovations-to-life-through-prototyping-and-manufacturing-10-12-23 [to_ping] => [pinged] => [post_modified] => 2024-08-22 11:31:25 [post_modified_gmt] => 2024-08-22 15:31:25 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4285 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [3] => WP_Post Object ( [ID] => 3338 [post_author] => 3 [post_date] => 2019-08-26 13:59:23 [post_date_gmt] => 2019-08-26 13:59:23 [post_content] => Due to a few technical difficulties, and to accommodate new and/or incoming awardees, NIH is extending the deadline to apply to their NIH Commercialization Accelerator Program (NIH CAP). The new deadline is 11:59 p.m. PDT (Pacific) FRIDAY, September 13, 2019. This is a cost free* customized commercialization (market readiness/growth) program. For 16 years, CAP has provided customized technical/business assistance to companies at different stages, and has a notable track record: 50 acquisitions (including companies acquired by Sony, Zoll, Bruker, BioMarin, Illumina, Takeda, Google, Roche, etc.), 10 IPOs, and more than $1B in 3rd party funding raised. The program features:
  • world-class guidance from experienced domain professionals, including industry and technical specialists affiliated with Bayer Healthcare, Qualcomm, Baxter, Pfizer, Genetech, McKesson, Medtronic, CMS, Life Technology, etc.
  • Feedback and interaction from a range of stakeholders in the life sciences marketplace
  • Notable graduates of the CAP include: Sharklet, Lift Labs, (provide a few big and recognizable names)
  • Alumni benefit – Continued access to Larta’s network and resources post program!
*CAP participation is free of charge for program participating companies; however, participants are responsible for travel and lodging expenses associated with attending workshops and program related events. For more details on this program, including success data, eligibility and instructions, please visit: https://sbir.nih.gov/cap. [post_title] => DEADLINE EXTENDED! NIH SBIR/STTR Commercialization Accelerator Program (CAP) [post_excerpt] => [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => deadline-extended-nih-cap [to_ping] => [pinged] => [post_modified] => 2019-08-26 13:59:23 [post_modified_gmt] => 2019-08-26 13:59:23 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=3338 [menu_order] => 88 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) ) [post_count] => 4 [current_post] => -1 [before_loop] => 1 [in_the_loop] => [post] => WP_Post Object ( [ID] => 4439 [post_author] => 3 [post_date] => 2024-07-30 15:29:07 [post_date_gmt] => 2024-07-30 19:29:07 [post_content] =>

CFB Client, IAMBIC has been awarded approximately $1M in grant funding from the National Science Foundation Small Business Innovation Research program. IAMBIC is an innovative shoe company disrupting the centuries-old footwear industry with their sizeless, precision-fit footwear driven by proprietary AI algorithms. This substantial funding from NSF enables IAMBIC to scale its cutting-edge precision-fit shoe design and manufacturing.

The Center for Biotechnology and its accelerator programs have been instrumental in assisting IAMBIC with their SBIR pursuits and commercialization development.

Read more about IAMBIC and their recent funding here.

[post_title] => IAMBIC Receives $1 Million NSF SBIR Phase II Grant [post_excerpt] => This substantial funding from NSF enables IAMBIC to scale its operations. [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => iambic-receives-1-million-nsf-sbir-phase-ii-grant [to_ping] => [pinged] => [post_modified] => 2024-08-09 15:38:43 [post_modified_gmt] => 2024-08-09 19:38:43 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4439 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [comment_count] => 0 [current_comment] => -1 [found_posts] => 260 [max_num_pages] => 87 [max_num_comment_pages] => 0 [is_single] => [is_preview] => [is_page] => [is_archive] => [is_date] => [is_year] => [is_month] => [is_day] => [is_time] => [is_author] => [is_category] => [is_tag] => [is_tax] => [is_search] => [is_feed] => [is_comment_feed] => [is_trackback] => [is_home] => 1 [is_privacy_policy] => [is_404] => [is_embed] => [is_paged] => [is_admin] => [is_attachment] => [is_singular] => [is_robots] => [is_favicon] => [is_posts_page] => [is_post_type_archive] => [query_vars_hash:WP_Query:private] => 325c4f9f1aebaa5ec90666fa54175ba0 [query_vars_changed:WP_Query:private] => [thumbnails_cached] => [allow_query_attachment_by_filename:protected] => [stopwords:WP_Query:private] => [compat_fields:WP_Query:private] => Array ( [0] => query_vars_hash [1] => query_vars_changed ) [compat_methods:WP_Query:private] => Array ( [0] => init_query_flags [1] => parse_tax_query ) )

IAMBIC Receives $1 Million NSF SBIR Phase II Grant

More Information

Getting Serious About BioEntrepreneurship in New York

More Information

“Bring Your New Technology Innovations to Life Through Prototyping and Manufacturing” 10/12/23

More Information

DEADLINE EXTENDED! NIH SBIR/STTR Commercialization Accelerator Program (CAP)

More Information